Belgium Allows Fully Autonomous Vehicles To Be Tested on the Public Highway
Client Alert | 1 min read | 05.03.18
On May 1, 2018, Belgium became one of the first European countries to allow fully autonomous vehicles to be tested on the public highway without a driver.
Back in September 2016, the Belgian federal government issued a set of guidelines for organizations wishing to test driver assistance and partially or fully automated vehicle technologies on public roads or in other public places within Belgium. These guidelines list the minimum conditions and safety requirements which the organization responsible for the testing must comply with in order to guarantee road safety and minimize potential risks.
However, implementation of these guidelines required adaptation of the Belgian traffic code to allow for their unambiguous application. Therefore, on March 18, 2018, the Belgian federal government passed a royal decree introducing a new provision (article 59/1) which allows the federal Minister of Mobility to deviate from all provisions of the Belgian traffic code in the framework of experiments with automated vehicles. Such deviation is subject to conditions and must be for a limited time.
As a result of the adoption of this new provision, the federal Minister of Mobility can now allow the testing of fully autonomous vehicles on public roads without a driver, but the test must be supervised by an operator acting from a control room outside the car.
Any organization interested in carrying out such tests can file an application at the Ministry of Mobility.
Contacts
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief


